Redeye: IRRAS - Positive growth sales trajectory, but immediate need for cash

2022-04-29 07:40:00

Redeye returns with an in-depth take on the Q1 report following the conference call and discussion with management. Its financial situation continues to overshadow any commercial progress at this point but once sorted, we believe its sales growth should begin to be more recognized by investors. We adjust our fair value range again following a decline in the share since our last update.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.